Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Four to fifteen Grade 1/2 actinic keratosis lesions (AKs) on one upper extremity~Exclusion Criteria:~* Pregnancy~* grade 3 and/or atypical \>1cm AKs within Treatment Area~* history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis~* lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the Treatment Area~* skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy~* Subject is immunosuppressed~* unsuccessful outcome from previous ALA-PDT therapy~* currently enrolled in an investigational drug or device study~* has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment~* known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol)~* use of the following topical preparations on the extremity to be treated:~  * Keratolytics including urea (greater than 5%), alpha hydroxyacids \[e.g.glycolic acid, lactic acid, etc. greater than 5%\], salicylic acid (greater than 2%) within 2 days of initiation of treatment.~ * Cryotherapy within 2 weeks of initiation of treatment~ * Retinoids, including tazarotene, adapalene, tretinoin, within 4 weeks of initiation of treatment.~ * Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU, diclofenac, ingenol mebutate, imiquimod or other topical treatments for AK within 8 weeks of initiation of treatment.~* use of systemic retinoid therapy within 6 months of initiation of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALA (Type: EXPERIMENTAL): None
- Vehicle (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).